Bristol cuts its BCMA losses
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
